Mendaza, S.; Ulazia-Garmendia, A.; Monreal-Santesteban, I.; CĂłrdoba, A.; AzĂşa, Y.R.d.; Aguiar, B.; Beloqui, R.; Armendáriz, P.; Arriola, M.; MartĂn-Sánchez, E.;
et al. ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2020, 21, 903.
https://doi.org/10.3390/ijms21030903
AMA Style
Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, CĂłrdoba A, AzĂşa YRd, Aguiar B, Beloqui R, Armendáriz P, Arriola M, MartĂn-Sánchez E,
et al. ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2020; 21(3):903.
https://doi.org/10.3390/ijms21030903
Chicago/Turabian Style
Mendaza, Saioa, Ane Ulazia-Garmendia, Iñaki Monreal-Santesteban, Alicia CĂłrdoba, Yerani Ruiz de AzĂşa, Begoña Aguiar, Raquel Beloqui, Pedro Armendáriz, Marta Arriola, Esperanza MartĂn-Sánchez,
and et al. 2020. "ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer" International Journal of Molecular Sciences 21, no. 3: 903.
https://doi.org/10.3390/ijms21030903
APA Style
Mendaza, S., Ulazia-Garmendia, A., Monreal-Santesteban, I., CĂłrdoba, A., AzĂşa, Y. R. d., Aguiar, B., Beloqui, R., Armendáriz, P., Arriola, M., MartĂn-Sánchez, E., & Guerrero-Setas, D.
(2020). ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 21(3), 903.
https://doi.org/10.3390/ijms21030903